Division of Cooper Cos. Inc.
Latest From Origio AS
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Deal will boost Cooper’s share of the $220 million global IVF market from 7% to 39%.
- Medical Devices
- Therapeutic Areas
- Gynecological, Urological
- MediCult AS
- Western Europe
- Parent & Subsidiaries
- Cooper Cos. Inc.
- Senior Management
Jeannett Hvidkjaer, EVP, CFO
David T Hansen, Pres. & Managing Dir.
Marie-Louise Haxthausen, VP, Global Mktg.
Susanne H Hauschildt Bendz, PhD, CSO & EVP, Innovation & Regulatory
- Contact Info
Phone: (45) 45 4679 0311
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.